Use of ApoA-1 to Treat and Prevent Pro-Inflammatory Conditions

Tech ID: 28727 / UC Case 2011-788-0


UCLA researchers in the Department of Obstetrics and Gynecology have discovered that ApoA-I can be used to treat and prevent pro-inflammatory skin conditions.


Inflammation is a standard immune signaling process that is strongly associated with stress and is connected to various diseases. Inflammation is activated to fight infection or invasion of potentially deleterious biological agents and to drive wound healing. While essential for these functions, inflammation can also exert detrimental effects. An unbalanced systemic inflammatory reaction can induce shock, derangement of microcirculation, and defects in coagulation. Antioxidants such as vitamin C, coffeeberry, and resveratrol have been used in the prevention and treatment of skin and systemic pro‐inflammatory conditions.

Apolipoprotein A1 (ApoA‐1) is the major protein component of HDL particles in the plasma. The protein, as a component of HDL particles, enables efflux of fat molecules by accepting fats from within cells for transport outside of the cells. ApoA‐1 has been shown to have extremely strong and specific antioxidant activity. 


Researchers at UCLA have shown that ApoA‐1 can significantly reduce the viability and proliferation of pro-inflammatory ID8 cells (mouse epithelial ovarian cancer cell line). An ApoA‐1 mimetic (D‐4f) was able to induce synthesis of mnSOD mRNA and protein, which inhibits cancer cell growth. To date, ApoA‐1 has never been used for this purpose. However, the mechanism of action has already been determined, which will enable more directed development for therapeutic use.


Therapeutic application to inhibit inflammation:

  • Epithelial cancers
  • Alzheimer’s disease
  • Atherosclerosis
  • Inflammatory skin diseases
  • Inflammatory bowel syndrome
  • Other autoimmune diseases


  • ApoA-I has never been used as a therapeutic before
  • Extremely strong and specific antioxidant activity
  • Part of mechanism of action determined

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 10,208,103 02/19/2019 2011-788
Germany Issued Patent 60 2012 043 827.4 03/07/2018 2011-788
France Issued Patent 2751126 03/07/2018 2011-788
United Kingdom Issued Patent 2751126 03/07/2018 2011-788
Japan Issued Patent 6078067 01/20/2017 2011-788
United States Of America Issued Patent 9,241,976 01/26/2016 2011-788


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Farias-Eisner, Robin P.

Other Information


Inflammatory diseases, ApoA-1, antioxidant, mimetic peptide, tumor suppression, epithelial cancers, Alzheimer’s diseases, inflammatory skin disease, inflammatory bowel diseases, atherosclerosis

Categorized As